Revance Therapeutics (RVNC) Scheduled to Post Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.17. The business had revenue of $69.80 million during the quarter, compared to analysts’ expectations of $64.02 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Trading Up 6.8 %

Shares of RVNC stock opened at $4.38 on Wednesday. The stock has a 50 day simple moving average of $4.76 and a 200-day simple moving average of $6.21. The company has a market cap of $456.48 million, a price-to-earnings ratio of -1.16 and a beta of 1.16. Revance Therapeutics has a 12-month low of $3.21 and a 12-month high of $37.98.

Wall Street Analyst Weigh In

A number of research firms have commented on RVNC. Barclays reduced their target price on Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, January 29th. Mizuho downgraded shares of Revance Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $16.00 to $9.00 in a report on Monday, January 29th. Piper Sandler dropped their target price on shares of Revance Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, February 29th. The Goldman Sachs Group boosted their price target on Revance Therapeutics from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, March 1st. Finally, Needham & Company LLC dropped their price objective on Revance Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.75.

Insider Transactions at Revance Therapeutics

In other Revance Therapeutics news, CFO Tobin Schilke sold 9,361 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $47,179.44. Following the sale, the chief financial officer now owns 192,666 shares in the company, valued at approximately $971,036.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Tobin Schilke sold 9,361 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the sale, the chief financial officer now directly owns 192,666 shares in the company, valued at $971,036.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Dustin S. Sjuts sold 9,211 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $46,423.44. Following the sale, the president now directly owns 167,550 shares in the company, valued at approximately $844,452. The disclosure for this sale can be found here. Insiders sold a total of 29,089 shares of company stock valued at $143,642 in the last ninety days. Corporate insiders own 3.50% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.